

EMMPRIN (1.BB.218): sc-71038

BACKGROUND

Extracellular matrix metalloproteinase inducer, EMMPRIN (also designated basigin or CD147), is involved in the regulation of matrix remodeling at the epidermal-dermal interface. EMMPRIN stimulates the production of interstitial collagenase, gelatinase A, stromelysin-1 and various metalloproteinases (MMPs) by fibroblasts. These enzymes, which are typically increased during tissue degradation and wound healing, are important factors in cancer invasion and metastasis.

CHROMOSOMAL LOCATION

Genetic locus: BSG (human) mapping to 19p13.3.

SOURCE

EMMPRIN (1.BB.218) is a mouse monoclonal antibody raised against the T-cell leukemic cell line Peer of human origin.

PRODUCT

Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

EMMPRIN (1.BB.218) is recommended for detection of EMMPRIN of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10⁶ cells).

Suitable for use as control antibody for EMMPRIN siRNA (h): sc-35298, EMMPRIN shRNA Plasmid (h): sc-35298-SH and EMMPRIN shRNA (h) Lentiviral Particles: sc-35298-V.

Molecular Weight of EMMPRIN: 55 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200, WI-38 whole cell lysate: sc-364260 or A2058 whole cell lysate: sc-364178.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850. 4) Immunohistochemistry: use m-IgGκ BP-HRP: sc-516102 with DAB, 50X: sc-24982 and Immunohistomount: sc-45086, or Organo/Limonene Mount: sc-45087.


RESEARCH USE

For research use only, not for use in diagnostic procedures.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



EMMPRIN (1.BB.218): sc-71038. Western blot analysis of EMMPRIN expression in HeLa (A), WI-38 (B) and A2058 (C) whole cell lysates.



EMMPRIN (1.BB.218) sc-71038. Immunofluorescence staining of methanol-fixed HeLa cells showing membrane localization (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded lower stomach tissue showing membrane and cytoplasmic staining of glandular cells (B).

SELECT PRODUCT CITATIONS

- Chen, T. and Zhu, J. 2010. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. *Med. Oncol.* 27: 1185-1191.
- Morais-Santos, F., et al. 2014. Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. *Endocr. Relat. Cancer* 21: 27-38.
- Valença, I., et al. 2015. Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. *J. Cell. Mol. Med.* 19: 723-733.
- Miranda-Gonçalves, V., et al. 2016. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. *Oncotarget* 7: 46335-46353.
- Pinheiro, C., et al. 2017. GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior. *Oncotarget* 8: 63835-63845.
- Silva, E.C.A., et al. 2018. The clinicopathological significance of mono-carboxylate transporters in testicular germ cell tumors. *Oncotarget* 9: 20386-20398.
- Alves, W.E.F.M., et al. 2019. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy. *BMC Cancer* 19: 1173.
- Pereira-Nunes, A., et al. 2020. Targeting lactate production and efflux in prostate cancer. *Biochim. Biophys. Acta Mol. Basis Dis.* 1866: 165894.



See **EMMPRIN (B-5): sc-46700** for EMMPRIN antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor® 488, 546, 594, 647, 680 and 790.